CORE

🇺🇦   make metadata, not war

    206 research outputs found

    Cartera vencida en la rentabilidad de una cooperativa de ahorro y crédito del Ecuador, año 2023

    Author
    Publication venue
    'Universidad Cesar Vallejo'
    Publication date
    Field of study
    Get PDF
    El actual estudio se enfocó en determinar la incidencia de la cartera vencida en la rentabilidad de una cooperativa de ahorro y crédito del Ecuador, año 2023. En vista de ello, se usó la investigación básica, enfoque cuantitativo, diseño no experimental, correlacional causal y transversal, siendo la muestra de 60 colaboradores de la institución objeto de revisión y la técnica fue la encuesta. Los principales hallazgos fueron que una mejor gestión de la cartera vencida conduce a una mayor rentabilidad (Rho Spearman de 0.437; p=0.000). El análisis, de igual modo, mostró que la cartera vencida de consumo se asocia significativamente con la rentabilidad de la cooperativa (Rho Spearman de 0.335 y p=0.009). Al igual que, la cartera vencida de microcrédito (Rho Spearman de 0.364 y p=0.004) y la cartera vencida de inmobiliario (Rho Spearman de 0.487 y p= 0.000). Por lo cual, se concluyó que la optimización de la gestión de la cartera vencida puede ser un elemento clave para aumentar la rentabilidad de una cooperativa de ahorro y crédito del Ecuador
    Repositorio Institucional Universidad César Vallejo: Página de inicio

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Author
    Publication venue
    Intensive Care Medicine
    Publication date
    Field of study
    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
    University of Liverpool Repository
    Queen's University Belfast Research Portal
    Serveur académique lausannois
    Archivio Istituzionale della Ricerca- Università degli Studi di Foggia
    Spiral - Imperial College Digital Repository
    Queen Mary Research Online
    Archivio Istituzionale della Ricerca- Università del Piemonte Orientale
    Archivio istituzionale della ricerca - Università di Palermo
    Archivio istituzionale della ricerca - Università di Trieste
    Ghent University Academic Bibliography
    Ktisis
    Queensland University of Technology ePrints Archive
    Apollo (Cambridge)
    King's Research Portal
    Recommended from our members

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Author
    Publication venue
    'Organisation for Economic Co-Operation and Development (OECD)'
    Publication date
    Field of study
    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
    Apollo (Cambridge)
    Recommended from our members

    Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Author
    Publication venue
    Intensive Care Medicine
    Publication date
    Field of study
    Get PDF
    The original version of this article unfortunately contained a mistake
    Apollo (Cambridge)

    Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    Institutional Repository Universiteit Antwerpen

    Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics
    Archivio Istituzionale della Ricerca - Università degli Studi di Pavia
    The University of Manchester - Institutional Repository
    Recommended from our members

    Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    BackgroundSparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis.MethodsPROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin–angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850.FindingsBetween Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (−42·8%, 95% CI −49·8 to −35·0, with sparsentan versus −4·4%, −15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals.InterpretationOver 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function
    University of Miami: Scholarship Miami
    The University of Manchester - Institutional Repository
    Recommended from our members

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Author
    Publication venue
    Intensive Care Medicine
    Publication date
    Field of study
    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat
    Apollo (Cambridge)

    Search for the Bs0→μ+μ−γB_s^0 \rightarrow \mu^+\mu^-\gamma decay

    Author
    Publication venue
    HAL CCSD
    Publication date
    Field of study
    No full text
    International audienceA search for the fully reconstructed Bs0→μ+μ−γB_s^0 \rightarrow \mu^+\mu^-\gamma decay is performed at the LHCb experiment using proton-proton collisions at s=13\sqrt{s}=13 TeV corresponding to an integrated luminosity of 5.4 fb−15.4\,\mathrm{fb^{-1}}. No significant signal is found and upper limits on the branching fraction in intervals of the dimuon mass are set \begin{align} {\cal B}(B_s^0 \rightarrow \mu^+\mu^-\gamma) < 4.2\times10^{-8},~&m(\mu\mu)\in[2m_\mu,~1.70]\,\mathrm{GeV/c^2} ,\nonumber {\cal B}(B_s^0 \rightarrow \mu^+\mu^-\gamma) < 7.7\times10^{-8},~&m(\mu\mu)\in[1.70,~2.88]\,\mathrm{GeV/c^2},\nonumber {\cal B}(B_s^0 \rightarrow \mu^+\mu^-\gamma) < 4.2\times10^{-8},~&m(\mu\mu)\in[3.92 ,~m_{B_s^0}]\,\mathrm{GeV/c^2},\nonumber \end{align} at 95% confidence level. Additionally, upper limits are set on the branching fraction in the [2mμ, 1.70] GeV/c2[2m_\mu,~1.70]\,\mathrm{GeV/c^2} dimuon mass region excluding the contribution from the intermediate ϕ(1020)\phi(1020) meson, and in the region combining all dimuon-mass intervals
    HAL-IN2P3

    Comprehensive analysis of local and nonlocal amplitudes in the B0→K∗0μ+μ−B^0\rightarrow K^{*0}\mu^+\mu^- decay

    Author
    Publication venue
    HAL CCSD
    Publication date
    Field of study
    No full text
    International audienceA comprehensive study of the local and nonlocal amplitudes contributing to the decay B0→K∗0(→K+π−)μ+μ−B^0\rightarrow K^{*0}(\to K^+\pi^-) \mu^+\mu^- is performed by analysing the phase-space distribution of the decay products. The analysis is based on \proton\proton collision data corresponding to an integrated luminosity of 8.4fb−1^{-1} collected by the LHCb experiment. This measurement employs for the first time a model of both one-particle and two-particle nonlocal amplitudes, and utilises the complete dimuon mass spectrum without any veto regions around the narrow charmonium resonances. In this way it is possible to explicitly isolate the local and nonlocal contributions and capture the interference between them. The results show that interference with nonlocal contributions, although larger than predicted, only has a minor impact on the Wilson Coefficients determined from the fit to the data. For the local contributions, the Wilson Coefficient C9C_9, responsible for vector dimuon currents, exhibits a 2.1σ2.1\sigma deviation from the Standard Model expectation. The Wilson Coefficients C10C_{10}, C9′C_{9}' and C10′C_{10}' are all in better agreement than C9C_{9} with the Standard Model and the global significance is at the level of 1.5σ1.5\sigma. The model used also accounts for nonlocal contributions from B0→K∗0[τ+τ−→μ+μ−]B^{0}\to K^{*0}\left[\tau^+\tau^-\to \mu^+\mu^-\right] rescattering, resulting in the first direct measurement of the bsττb s\tau\tau vector effective-coupling C9τC_{9\tau}
    HAL-IN2P3
    HAL AMU
    HAL Clermont Université
    HAL Université de Savoie
    • …
    corecore